Skip to main content
. Author manuscript; available in PMC: 2019 Oct 9.
Published in final edited form as: J Am Coll Cardiol. 2018 Oct 9;72(15):1856–1869. doi: 10.1016/j.jacc.2018.07.071

Figure 1: Summary of Reductions in Major Adverse Cardiac Events in recent SGLT2-i Trials.

Figure 1:

MACE, major adverse cardiac event; MI, myocardial infarction; SGLT2-i, sodium-glucose cotransporter 2 inhibitor. Both empagliflozin and canagliflozin significantly reduced MACE-3 and heart failure hospitalization in EMPA-REG and CANVAS Program, respectively. A reduction in cardiovascular death and all-cause mortality was observed with use of empagliflozin.